It depends heavily on the class of peptide, and the underlying reason is receptor desensitisation — continuous, high-level stimulation of a receptor triggers a protective physiological response that gradually blunts its own effect, a phenomenon known as tachyphylaxis.
Growth hormone secretagogues are the clearest example: continuous stimulation of the GHRH and ghrelin (GHS-R1a) receptors makes the pituitary progressively less responsive, so the same dose produces a smaller effect over time. This is why GH-secretagogue protocols (CJC-1295, Ipamorelin, GHRP-6) are typically run on structured cycles — commonly 8–12 weeks on with 4–6 weeks off, or shorter 5-days-on/2-days-off patterns — to let receptor sensitivity reset.
Not every peptide follows this pattern. GLP-1 receptor agonists like semaglutide are specifically designed for continuous, uninterrupted use, and stopping typically leads to a reversal of their effects rather than improved sensitivity. Whether a specific peptide needs cycling comes down to its individual receptor pharmacology — there's no single universal rule across all research peptides.
Study-backed guides, dosing protocols, and the full research peptide collection — all in one place.